La FFCD a été représentée à l'ASCO 2022, decouvrez les 2 posters :

• PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma - D. Tougeron
• PRODIGE 25 - FOLFA : Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers. Results of a randomized FOLFA phase II trial - JL Legoux